ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019
Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04584645 (Increasing Influenza Vaccination in Individuals With Cardiovascular Conditions), which is not on this map. Cited by 177 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Increasing Influenza Vaccination in Individuals With Cardiovascular Conditions: Assessing the Effectiveness of a Digital Intervention in a Decentralized Randomized Controlled Trial
Who cites it
177 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2024Guideline
- Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2022Guideline
- Pooled it
- Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study.The Lancet. Global health · 2020Pooled it
- A systematic review and meta-analysis of cross-reactivity of antibodies induced by H7 influenza vaccine.Human vaccines & immunotherapeutics · 2020Pooled it
- Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2019Guideline
- Nudges to Clinicians and Patients for Influenza Vaccines During Visits: The BE IMMUNE Randomized Clinical Trial.JAMA internal medicine · 2026Trial
- Impact of Real-Time, On-Demand Influenza and Respiratory Syncytial Virus Testing at Point-of-Care on Antibiotic Prescribing and Clinical Outcome in Pediatric Outpatients With Acute Respiratory Illness: A Prospective, Quasi-Randomized, Controlled Study.Influenza and other respiratory viruses · 2026Trial
- Antibody response to sequential vaccination with cell culture, recombinant, or egg-based influenza vaccines among U.S. adults.Human vaccines & immunotherapeutics · 2024Trial
- Are interactive and tailored data visualizations effective in promoting flu vaccination among the elderly? Evidence from a randomized experiment.Journal of the American Medical Informatics Association : JAMIA · 2024Trial
- Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines.Nature communications · 2024Trial
- Text Message Reminders for the Second Dose of Influenza Vaccine for Children: An RCT.Pediatrics · 2022Trial
- Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- An evaluation of a test-negative design for EV-71 vaccine from a randomized controlled trial.Human vaccines & immunotherapeutics · 2021Trial
- Impaired memory B-cell recall responses in the elderly following recurrent influenza vaccination.PloS one · 2021Trial
- Electronic Health Record Portal Messages and Interactive Voice Response Calls to Improve Rates of Early Season Influenza Vaccination: Randomized Controlled Trial.Journal of medical Internet research · 2020Trial
- Effect of Automated Immunization Registry-Based Telephonic Interventions on Adult Vaccination Rates in Community Pharmacies: A Randomized Controlled Trial.Journal of managed care & specialty pharmacy · 2019Trial
- Strategies for Improving Influenza Vaccination Rates in Patients with Chronic Renal Disease.Deutsches Arzteblatt international · 2019Trial
- Influenza A deletion-containing viral genome production is altered by metabolites, metabolic signaling molecules, and cyanobacterial extracts.Applied and environmental microbiology · 2026Article
- Disparities in Adult Influenza Vaccination in the United States: Analysis of 2023 BRFSS Data.Infectious diseases and therapy · 2026Article
117 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
29 authors.
Funding
Abstract
backgroundThe severity of the 2017-2018 influenza season in the United States was high, with influenza A(H3N2) viruses predominating. Here, we report influenza vaccine effectiveness (VE) and estimate the number of vaccine-prevented influenza-associated illnesses, medical visits, hospitalizations, and deaths for the 2017-2018 influenza season.
methodsWe used national age-specific estimates of 2017-2018 influenza vaccine coverage and disease burden. We estimated VE against medically attended reverse-transcription polymerase chain reaction-confirmed influenza virus infection in the ambulatory setting using a test-negative design. We used a compartmental model to estimate numbers of influenza-associated outcomes prevented by vaccination.
resultsThe VE against outpatient, medically attended, laboratory-confirmed influenza was 38% (95% confidence interval [CI], 31%-43%), including 22% (95% CI, 12%-31%) against influenza A(H3N2), 62% (95% CI, 50%-71%) against influenza A(H1N1)pdm09, and 50% (95% CI, 41%-57%) against influenza B. We estimated that influenza vaccination prevented 7.1 million (95% CrI, 5.4 million-9.3 million) illnesses, 3.7 million (95% CrI, 2.8 million-4.9 million) medical visits, 109 000 (95% CrI, 39 000-231 000) hospitalizations, and 8000 (95% credible interval [CrI], 1100-21 000) deaths. Vaccination prevented 10% of expected hospitalizations overall and 41% among young children (6 months-4 years).
conclusionsDespite 38% VE, influenza vaccination reduced a substantial burden of influenza-associated illness, medical visits, hospitalizations, and deaths in the United States during the 2017-2018 season. Our results demonstrate the benefit of current influenza vaccination and the need for improved vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.